Replies to post #6648 on Revance Therapeutics Inc (RVNC)

[alertmeipp]

Explain to me why payers would want patients to try a more expensive drug first?

[DewDiligence]

Here’s_what_RVNC_has_actually_said_about CD insurance coverage; from the 4Q23 CC:

https://finance.yahoo.com/news/q4-2023-revance-therapeutics-inc-114148486.html

…on the covered side of it, if you look at the commercial category within CD, it's about 60% of the overall CD lives. We're over 50% already.

I.e., Daxxify already has reimbursement coverage for 83% (0.5/0.6) of the commercial-insurance portion of CD market—as well as 100% of the Medicare portion of the market.

And within that [commercial portion of the market]…almost two thirds of that coverage is going to be first-line therapy.

In other words, step-edits apply to only about 1/3 of the CD commercial lives for which Daxxify is currently covered.

p.s. RVNC is projecting modest CD sales during 2024, so your admonitions about Daxxify's commercial ramp in CD are already embedded in RVNC’s guidance.